



NEW 1648
#

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,

Suvian Nesmith

23 Sept 2005

DATE

Attorney Docket No. B45158X1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Nathalie Garcon	23 September 2005
Serial No.:	09/807,657	Group Art Unit No.: 1648
Filed:	16 April 2001	Examiner: Z. Lucas
For:	Adjuvant Systems and Vaccines	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. Copies of each are enclosed.

This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Serial No.: 09/807,657
Group Art Unit No.: 1648

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Reid S. Willis
Attorney for Applicants
Registration No. 39,429

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7481
Facsimile (610) 270-5090

N:\Reid\apps\B45158X1\Supplemental IDS(3)

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Nathalie GarconFILING DATE
16 April 2001GROUP
1648**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,932,972	23 Aug. 2005	Stephenne, et al.			
	5,776,468	7 July 1998	Houser, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 0511855	29 Apr. 1992	EP				
	EP 0278940	25 Jan. 1988	EP				
	EP 0414374	19 July 1990	EP				
	EP 0198474	15 Apr. 1986	EP				
	EP 0304578	22 June 1988	EP				
	EP 0576478	17 Mar. 1992	EP				
	EP 0689454	14 Mar. 1994	EP				
	EP 0633784	24 Mar. 1993	EP				
	EP 0226846AB1	25 Nov. 1986	EP				
	EP 0299108AB1	17 July 1987	EP				
	EP 1231264 (GB 9515478.7)	4 Aug. 2000	EP				
	EP 00/02920	18 Dec. 1978	EP				
	EP 00/08728	20 Aug. 1979	EP				
	EP 01/11984	17 Dec. 1983	EP				
	GB 2220211	22 Jun 1989	UK				
	WO 93/019780	14 Oct. 1993	PCT				
	WO 88/09797 (EP 0362278)	15 Dec. 1988	PCT				
	GB 9805105 (WO 99/45957)	16 Sep. 1999	PCT				
	WO 91/14703	3 Oct. 1991	PCT				
	WO 01/17550A2	15 Mar. 2001	PCT				
	WO 96/33739	31 Oct. 1996	PCT				
	WO 96/02555	1 Feb. 1996	PCT				
	WO 93/10152	27 May 1993	PCT				
	WO 90/01496	22 Feb. 1990	PCT				
	WO 92/16231	1 Oct. 1992	PCT				

		WO 99/10375	4 Mar. 1999	PCT				
		WO 93/24148	9 Dec. 1993	PCT				
		WO 01/17551	15 Mar. 2001	PCT				
		WO 94/21292	29 Sep. 1994	PCT				

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. B45158X1	SERIAL NO. 09/807,657
	APPLICANT Nathalie Garcon			
	FILING DATE 16 April 2001		GROUP 1648	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Van den Eynde, et al., "Tumor Antigens Recognized by T Lymphocytes," <i>Int J. Clin Res</i> , 1997 27:81-86
	Correale, et al., "In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived from Prostate-Specific Antigen," <i>Journal of the National Cancer Institute</i> , 1997 89:293-300
	Robbins, et al., "Human Tumor Antigens Recognized by T Cells," <i>Current Opinion in Immunology</i> , 1996 8:628-636
	Andre, et al., "Inactivated Candidate Vaccines for Hepatitis A," <i>Melnick JL (ed.): Prog Med Virol, Basel, Karger</i> , 1990 37:72-95
	Eddleston, "Modern Vaccines," <i>The Lancet</i> , 1990 335:1142-1145
	Dalsgaard, "Saponin Adjuvants," <i>Springer-Verlag</i> , 1974 44:243-254
	Tiollais, et al., "The Hepatitis B Virus," <i>Nature</i> , 1985 317:489-495
	Harford, et al., "Expression of Hepatitis B Surface Antigen in Yeast," <i>Develop. Biol. Standard</i> , 1983 54:125-130
	Cregg, et al., "High-Level Expression and Efficient Assembly of Hepatitis B Surface Antigen in the Methylophilic Yeast, <i>Pichia Pastoris</i> ," <i>Biotechnology</i> 1987 5:479-485
	Vogel, et al., "A Compendium of Vaccine Adjuvants and Excipients," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995 Chapter 7:141-228
	Newman, et al., "Adjuvant Formulation Concerns," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 1, 4.6:26-27
	Gupta, et al., "Adjuvant Properties of Aluminum and Calcium Compounds," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 8:229-248

	Hem, et al., "Structure and Properties of Aluminum-Containing Adjuvants," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 9:249-276
	Ulrich, et al., "Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 21:495-524
	Purcell, "Approaches to Immunization against Hepatitis A Virus," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:41-46
	Day, et al., "Evaluation of the Human B Lymphocyte Response to Hepatitis A Virus," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:69-71
	Andre, "Development of a Vaccine against Hepatitis A," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:85-87
	Sjogren, et al., "Inactivated Hepatitis A Vaccine in Adults: Comparison of Dose Schedules and Evaluation of Different Preparations," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:88-90
	Ellerbeck, et al., "Safety and Immunogenicity of an Inactivated Hepatitis A Virus Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:91-93
	Lewis, et al., "Use of a Live, Attenuated Hepatitis A Vaccine to Prepare a Highly Purified, Formalin-inactivated Hepatitis A Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:94-97
	Ambrosch, et al., "Comparison of HAV Antibodies Induced by Vaccination, Passive Immunization, and Natural Infection", <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:98-100
	Karayiannis, et al., "Vaccination of Tamarins with a Recombinant Vaccinia-Hepatitis A Virus Protects against HAV Infection," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:101-104
	Weitz, et al., "Empty Hepatitis A Virus Particles in Vaccines," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:104-108
	Heinricy, et al., "Schedule-dependent Immune Response to Hepatitis A Vaccination," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:108-110
	Mao, et al., "Further Studies of Attenuated Live Hepatitis A Vaccine (H2 Strain) in Humans," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:110-111
	Fuchs, et al., "Protection from Infection with Woodchuck Hepatitis Virus (WHV) by Immunization with Recombinant Core Protein of WHV and HGV," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 3:267-270
	Margolis, et al., "Immunization Strategies for the Control of Hepatitis A in the United States," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:724-726
	Mahoney, "Cost of Production of Plasma-derived Hepatitis B Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:730-731

	De Knecht, et al., "Low-Dose Hepatitis B Vaccination with Recombinant Vaccine in Medical Students," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:741-744
	Lee, et al., "Immunogenicity and Protective Efficacy on Low-Dose Hepatitis B Vaccine in Newborns of HBsAg-Carrier Mothers," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:-744-746
	Yamauchi, et al., "Reduced Immunogenicity of Hepatitis B Vaccine in Patients with Chronic Non-A, Non-B (Type C) Hepatitis," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:747-748
	Yeoh, et al., "Determinants of Immunogenicity and Efficacy of Hepatitis B Vaccine in Infants," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:749-752
	Lelie, et al., "Prevention of the Hepatitis B Virus Carrier State in Infants of Mothers with High and Low Serum Levels of HBV-DNA," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:753-756
	Boxall, et al., "HBV-DNA Levels in Hepatitis B Carrier Mothers; Relationship with Protection against Perinatal Transmission by Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:757-759
	Hwang, et al., "Five-Year Follow-up of HBV Vaccination with Plasma-derived Vaccine in Neonates: Evaluation of Immunogenicity and Efficacy against Perinatal Transmission," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:759-761
	Wainwright, et al., "Duration of Immunogenicity and Efficacy of Hepatitis B Vaccine in a Yupik Eskimo Population-Preliminary Results of an 8-Year Study," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:762-766
	Hadler, et al., "Evaluation of Long-Term Protection by Hepatitis B Vaccine for Seven to Nine Years in Homosexual Men," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:766-768
	Milich, et al., "Importance of Subtype in the Immune Response to the PreS2 Region," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:768-773
	Hattum, et al., "In Vitro Anti-HBs Production by Individual B Cells of Responders to Hepatitis B Vaccine Who Subsequently Lost Antibody," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:774-776
	Lee, et al., "The Second Booster for the Previously Hepatitis B Vaccine-immunized High-Risk Children," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:776-778
	Takahashi, et al., "Identification of Low-Level Hepatitis B Viral Genome in Hepatitis B Vaccine Nonresponders in Japan," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:779-781
	Sciariada, et al., "Immune Response to Hepatitis B Vaccine in Persons with Anti-HBc Alone," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:782-784

	Schödel, et al., "Oral Immunization of Mice with Hepatitis B Virus B Cell and T Cell Epitopes Expressed in Salmonella Vaccine Strains," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:784-787
	Fay, et al., "Strategies for Implementing Successful Hepatitis B Vaccination Programs," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:831-833
	Milich, "A Synthetic PreS2 Immunogen," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:840-844
	Michel, et al., "Hepatitis B Virus Surface Antigen (HBsAg) as Carrier for Foreign Antigenic Determinants," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:844-846
	Robinson, et al., "Hepatitis B Virus Antigens Expressed by Live Salmonella Vaccine Strains Elicit Humoral and Cellular Immune Responses in Mice," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:847-849
	Tong, et al., "Immunoprophylaxis of Neonates against Hepatitis B," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:849-855
	Grob, et al., "Unresolved Issues in Hepatitis B Immunization," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:856-860
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

n:\Reid\patapps\b45158\pto 1449 form.doc